CRESCENT BIOPHARMA, INC. Operating Lease Right-of-Use Assets
CRESCENT BIOPHARMA, INC. (CBIO) had Operating Lease Right-of-Use Assets of $1.27 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-07-30
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.27M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.37M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.47M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.56M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.27M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $1.37M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $1.47M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.56M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.61M 10-Q · filed 2025-07-31 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-06-30 | $424.21K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $598.26K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $767.83K 10-K · filed 2025-02-13 |
| 2023-09-30 | $955.31K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $1.18M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $532.06K 10-Q · filed 2023-05-03 |
| 2022-12-31 | $751.17K 10-K · filed 2024-03-27 |
| 2022-09-30 | $965.02K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.17M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.38M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $1.58M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.77M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $1.96M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.14M 10-Q · filed 2021-05-03 |
| 2020-12-31 | $2.33M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.50M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $2.67M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $2.84M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $3.01M 10-K · filed 2021-03-02 |
| 2019-09-30 | $3.17M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $3.32M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $3.48M 10-Q · filed 2019-05-02 |
| 2019-01-01 | $3.60M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |